Boehringer Can't Shake Pradaxa Warning Label Claims

Law360, New York (July 19, 2013, 8:21 PM EDT) -- An Illinois federal judge on Thursday kept alive accusations that Boehringer Ingelheim Pharmaceuticals Inc. failed to warn a Louisiana man of bleeding risks associated with its oral anticoagulant Pradaxa, ruling the drugmaker hadn't shown its labeling carried the necessary disclosures.

U.S. District Judge David R. Herndon ruled that plaintiff Mark Jackson could move forward with allegations that Boehringer's Pradaxa, which is designed to reduce the risk of blood clots and stroke in people with abnormal heart rhythms, was defectively designed and sold without proper warning labels....
To view the full article, register now.




Case Information

Case Title

Jackson v. Boehringer Ingelheim Pharmaceuticals, Inc. et al

Case Number



Illinois Southern

Nature of Suit

Personal Inj. Prod. Liability


David R. Herndon

Date Filed

August 17, 2012

Law Firms


Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.